<i>H19</i> non-coding RNA in urine cells detects urothelial carcinoma: a pilot study

Gielchinsky, Ilan; Gilon, Michal; Abu-lail, Rasha; Matouk, Imad; Hochberg, Avraham; Gofrit, Ofer N.; Ben‐Dov, Iddo Z.

doi:10.1080/1354750x.2016.1276625

Cited by 14 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hua et al demonstrated that genetic variants in lncRNA H19 are associated with the risk of bladder cancer in a Chinese population [29]. Ariel et al revealed that H19 could serve as a prognostic tumor marker for the early recurrence of BC [30]; Gielchinsky et al demonstrated that urinary cell H19 is a highly sensitive test for urothelial carcinoma [31]. For the role of H19 in exosomes, a report by Conigliaro et al suggested that release of exosome-contained lncRNA H19 can modulate the endothelial cell phenotype of liver cancer cells [32].…”

Section: Discussionmentioning

confidence: 99%

Determination of Serum Exosomal H19 as a Noninvasive Biomarker for Bladder Cancer Diagnosis and Prognosis

Wang

Yang

et al. 2018

Med Sci Monit

View full text Add to dashboard Cite

BackgroundLong noncoding RNAs (lncRNA) contained in exosomes have been recognized as promising stable biomarkers in cancers. H19 is a well-known oncogenic lncRNA, but whether extracellular H19 is contained in exosomes and the clinical significance of exosomal H19 are poorly understood. The aim of this study was to assess serum-derived exosomal H19 lncRNA as a cancer predictive marker.Material/MethodsExosomes from serum of bladder cancer (BC) patients were isolated using the ExoQuick purification method and identified using transmission electron microscopy and nanoparticle tracking analysis. RT-qPCR was used for the measurement of H19 expression in serum or tissue samples.ResultsSerum H19 was little influenced by the treatment of RNase A alone but was dramatically downregulated when treated with RNase A and Triton ×100 simultaneously. The concentration of H19 was significantly higher in serum exosomes than in exosome-depleted supernatants in serum. Then, we validated that exosomal H19 is stable in serum by exposing serum samples to prolonged conditions of room temperature, 4°C, multiple freeze-thaw cycles, and low/high pH. Serum exosomal H19 of BC patients was positively correlated with total H19 level in paired BC tissues, and exosomal H19 was significantly downregulated in postoperative samples when compared to the paired preoperative samples. In addition, exosomal H19 level was significantly increased in serum of BC patients when compared to healthy people and benign disease patients. More importantly, Kaplan-Meier survival curve analysis showed that higher serum exosomal H19 level in BC patients was correlated with poorer survival.ConclusionsDetection of serum exosomal H19 shed light on using exosomal lncRNAs as a noninvasive diagnostic and prognostic biomarker for BC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Determination of Serum Exosomal H19 as a Noninvasive Biomarker for Bladder Cancer Diagnosis and Prognosis

Wang

Yang

et al. 2018

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…Eventually, 15 articles that qualified were included in this metaanalysis, comprising 5 articles concerning blood-based lncRNAs 10,11,15,16,18 and 10 involving urine-based ones. [5][6][7][8][9][12][13][14]17,19 Essential features of included studies Table 1 demonstrates the general characteristics of the included articles. A total of 43 studies from 15 articles published from 2006 to 2019 were included in our meta-analysis, including controls and 3370 bladder cancer patients; 21 studies involved Caucasian participants and 22 studies involved Asian participants.…”

Section: Bibliographic Retrievalmentioning

confidence: 99%

“…lncRNAs (>200 nt long) play key roles in regulating chromatin dynamics, gene expression, growth, differentiation, and development, and are abundantly expressed in a variety of cancers. 4 Many studies have reported that lncRNAs could be stable in body fluids and serve as diagnostic noninvasive biomarkers for bladder cancer; [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] however, difference existed among these studies in relation to the dependability of lncRNAs for detecting bladder cancer. Given this, we performed this meta-analysis to synthetically illuminate the diagnostic performance of circulating lncRNAs for bladder cancer based on published articles.…”

Section: Introductionmentioning

confidence: 99%

Circulating lncRNAs as noninvasive biomarkers in bladder cancer: A diagnostic meta-analysis based on 15 published articles

et al. 2020

View full text Add to dashboard Cite

Objective Owing to inconsistency between reports, a meta-analysis was designed to appraise the clinical implications of long non-coding RNAs (lncRNAs) in urine and blood for the diagnosis of bladder cancer. Methods Studies that met the criteria were acquired by bibliographic retrieval through PubMed, Embase, and the Cochrane Library. The pooled diagnostic performance was evaluated by calculating the area under the summary receiver operator characteristic (SROC) curve. The potential sources of heterogeneity were approached through meta-regression and subgroup analyses. All statistical analyses and plots were performed by RevMan 5.3, Meta-DiSc 1.4, and STATA 12.0. Results A total of 43 studies from 15 articles consisting of 3370 bladder cancer patients and 3212 controls were incorporated in our meta-analysis. lncRNAs in urine and blood performed relatively well in diagnosing bladder cancer, with a pooled sensitivity of 0.78, a specificity of 0.79, and an area under the SROC curve (AUC) of 0.86. H19 displayed the best diagnostic accuracy with a pooled AUC of 0.90, followed by UCA1 and MALAT1. The heterogeneity among studies was partly conducted by sample size, lncRNA existence form (cell-free or intracellular lncRNA), lncRNA origin (exosome- or non-exosome-based lncRNA), lncRNA profiling (single- or multiple-lncRNA), specimen types, and ethnicity. Conclusions lncRNAs in urine and blood may serve as noninvasive diagnostic biomarkers with great promise for bladder cancer, while their clinical values need to be examined through further synthetic forward-looking studies.

show abstract

“…In addition, other lncRNAs such as HOTAIR , MALAT1 , HOX-AS-2 , OTX2-AS1 , HYMAI , LINC00477 and LOC100506688 , have shown upregulation in urine exosomes of MIBC patients (Berrondo et al, 2016). In addition, H19 gene expression is significantly higher in BC patients, and its presence has been detected in the urine of 90.5% of patients versus 25.9% of healthy controls (AUC = 0.933) (Gielchinsky et al, 2017).…”

Section: Epigenetic Alterations As Biomarkers In Bc: the Potential Usmentioning

confidence: 99%

Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet

et al. 2019

View full text Add to dashboard Cite

Bladder cancer (BC) is the most common neoplasia of the urothelial tract. Due to its high incidence, prevalence, recurrence and mortality, it remains an unsolved clinical and social problem. The treatment of BC is challenging and, although immunotherapies have revealed potential benefit in a percentage of patients, it remains mostly an incurable disease at its advanced state. Epigenetic alterations, including aberrant DNA methylation, altered chromatin remodeling and deregulated expression of non-coding RNAs are common events in BC and can be driver events in BC pathogenesis. Accordingly, these epigenetic alterations are now being used as potential biomarkers for these disorders and are being envisioned as potential therapeutic targets for the future management of BC. In this review, we summarize the recent findings in these emerging and exciting new aspects paving the way for future clinical treatment of this disease.

show abstract

H19 non-coding RNA in urine cells detects urothelial carcinoma: a pilot study

Abstract: This pilot study shows that urinary cell H19 is a highly sensitive test for UC and pending verification could transform patient management.

Cited by 14 publications

References 28 publications

Determination of Serum Exosomal H19 as a Noninvasive Biomarker for Bladder Cancer Diagnosis and Prognosis

Determination of Serum Exosomal H19 as a Noninvasive Biomarker for Bladder Cancer Diagnosis and Prognosis

Circulating lncRNAs as noninvasive biomarkers in bladder cancer: A diagnostic meta-analysis based on 15 published articles

Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet

Contact Info

Product

Resources

About